Stocktoria
VERTEX PHARMACEUTICALS INC / MA VRTX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1991-07-24
VERTEX PHARMACEUTICALS INC / MA financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B |
| R&D expense | — | — | — | — | $3.1B | $1.8B | $1.8B | $1.4B | $1.3B | $1.0B |
| SG&A expense | $1.8B | $1.5B | $1.1B | $944.7M | $840.1M | $770.5M | $658.5M | $557.6M | $496.1M | $432.8M |
| Operating income | $4.2B | -$232.9M | $3.8B | $4.3B | $2.8B | $2.9B | $1.2B | $635.1M | $123.2M | $9.9M |
| Interest expense | — | — | — | — | — | $58.2M | $58.5M | $72.5M | $69.3M | — |
| Income tax | $690.0M | $784.1M | $760.2M | $910.4M | $388.3M | $405.2M | $218.1M | -$1.5B | -$107.3M | $16.7M |
| Net income | $4.0B | -$535.6M | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263.5M | -$112.1M |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| Operating cash flow | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B | $3.3B | $1.6B | $1.3B | $844.9M | $236.1M |
| Free cash flow | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B | $3.0B | $1.5B | $1.2B | $745.5M | $179.5M |
| Cash & equivalents | $5.1B | $4.6B | $10.4B | $10.5B | $6.8B | $6.0B | $3.1B | $2.7B | $1.7B | $1.2B |
| Inventory | $1.7B | $1.2B | $738.8M | $460.6M | $353.1M | $280.8M | $167.5M | $124.4M | $111.8M | $77.6M |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B | $11.8B | $8.3B | $6.2B | $3.5B | $2.9B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B | $3.1B | $2.2B | $1.8B | $1.5B | $1.6B |
| Shareholders' equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B | $8.7B | $6.1B | $4.4B | $2.0B | $1.3B |
Growth · year-over-year · Revenue CAGR 24.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +8.9% | +11.7% | +10.5% | +17.9% | +22.1% | +49.1% | +36.6% | +22.5% | +46.2% | +64.9% |
| Net income growth | — | -114.8% | +9.0% | +41.8% | -13.6% | +130.4% | -43.9% | +695.8% | — | — |
| EPS growth | — | -115.0% | +8.3% | +42.3% | -12.4% | +128.2% | -44.3% | +677.9% | — | — |
| Free cash flow growth | — | -123.7% | -15.0% | +63.0% | -19.5% | +100.4% | +27.2% | +57.6% | +315.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.